Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

Ping-Tee Tan; Mohamed Ismail Abdul Aziz; Fiona Pearce; Wan-Teck Lim; David Bin-Chia Wu; Kwong Ng

doi:10.1186/s12885-018-4223-y

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

BMC Cancer ◽

10.1186/s12885-018-4223-y ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 7

Author(s):

Ping-Tee Tan ◽

Mohamed Ismail Abdul Aziz ◽

Fiona Pearce ◽

Wan-Teck Lim ◽

David Bin-Chia Wu ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Egfr Mutation ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore

Journal of Medical Economics ◽

10.1080/13696998.2020.1819822 ◽

2020 ◽

Vol 23 (11) ◽

pp. 1330-1339

Author(s):

Mohamed Ismail Abdul Aziz ◽

Wayne Yong Xiang Foo ◽

Chee Keong Toh ◽

Wan-Teck Lim ◽

Kwong Ng

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Egfr Mutation ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”

Lung Cancer ◽

10.1016/j.lungcan.2020.06.014 ◽

2020 ◽

Vol 146 ◽

pp. 385-386

Author(s):

Min Huang ◽

Ralph P. Insinga ◽

Thomas Burke ◽

Ying Zhang ◽

Gilberto de Lima Lopes

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater

Lung Cancer ◽

10.1016/j.lungcan.2019.10.017 ◽

2019 ◽

Vol 138 ◽

pp. 88-94 ◽

Cited By ~ 10

Author(s):

Longjiang She ◽

Huabin Hu ◽

Mengting Liao ◽

Xuefeng Xia ◽

Yin Shi ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1847648 ◽

2020 ◽

pp. 1-9

Author(s):

Terence Khoo ◽

Lan Gao

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Egfr Mutation ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Tki ◽

First Line Treatment

Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer

Global & Regional Health Technology Assessment Italian Northern Europe and Spanish ◽

10.1177/2284240319855072 ◽

2019 ◽

Vol 2019 ◽

pp. 228424031985507

Author(s):

Ravasio R ◽

Tiseo M ◽

Pradelli L ◽

Bellone M ◽

Gervasi A ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis ◽

First Line Treatment

PCN36 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in Germany

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.086 ◽

2020 ◽

Vol 22 ◽

pp. S11

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

A Cost-Effectiveness Analysis of Gefitinib as the First Line Treatment in Patients With Positive Egfr Mutation In Metastatic or Locally Advanced non-Small Cell

Value in Health ◽

10.1016/j.jval.2015.09.1110 ◽

2015 ◽

Vol 18 (7) ◽

pp. A446 ◽

Cited By ~ 1

Author(s):

T Piha ◽

D Barbosa ◽

L Fahham

Keyword(s):

Cost Effectiveness ◽

Egfr Mutation ◽

Locally Advanced ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

26 Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation

Lung Cancer ◽

10.1016/s0169-5002(13)70026-6 ◽

2013 ◽

Vol 79 ◽

pp. S9

Author(s):

R. Douglas ◽

L. Campbell ◽

J. McAleese ◽

P. Scullin

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment

PCN82 Cost-Effectiveness Analysis of Erlotinib Versus Platinum Based Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer EGFR Activating Mutations

Value in Health ◽

10.1016/j.jval.2012.08.2122 ◽

2012 ◽

Vol 15 (7) ◽

pp. A424

Author(s):

P. Garrido ◽

G. López-Vivanco ◽

R. Rosell ◽

B. Espinós ◽

A. Castro-Gomez

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Activating Mutations ◽

Effectiveness Analysis ◽

Platinum Based Chemotherapy ◽

First Line Treatment

Optimal and Ensure Trials - Based Combined Cost-Effectiveness Analysis of Erlotinib Versus Chemotherapy for the First- Line Treatment of Asian Patients with Nonsquamous Non– Small-Cell Lung Cancer

Value in Health ◽

10.1016/j.jval.2016.08.274 ◽

2016 ◽

Vol 19 (7) ◽

pp. A888-A889

Author(s):

F Wen ◽

H Zheng ◽

P Zhang ◽

DW Hutton ◽

Q Li

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Asian Patients ◽

Effectiveness Analysis ◽

First Line Treatment